Dr. David M. Reese is Amgen’s inaugural executive vice president and chief technology officer, responsible for accelerating the use of technology and artificial intelligence across all facets of the company, as well as for the company’s Global Medical organization.

Dr. Reese joined Amgen in 2005 and served as executive vice president, Research and Development from 2018 to 2023. During this time, Amgen received approvals around the world for numerous innovative medicines and biosimilars, developed a robust pipeline of potential new medicines, and built a powerful discovery research capability.

Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization.